This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064211%3A_____%2F12%3A%230000213%21RIV14-MZ0-00064211/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064211%3A_____%2F12%3A%230000213%21RIV14-MZ0-00064211
rdf:type
n14:Vysledek skos:Concept
dcterms:description
Purpose: The objective of this study was to evaluate the feasibility, toxicity and efficacy of definitive radiochemotherapy with weekly cisplatin in head and neck cancer in a single institutional setting. Methods: Previously untreated patients with stage II-IV head and neck cancer were included. Radiotherapy consisted of 70 Gy/7 weeks/35 fractions. All patients received concurrent cisplatin 40 mg/m(2) weekly Results: Between 2/2002 and 8/2009, 148 consecutive patients (WHO <= 2, male to female ratio 6/1, median age 56 years) were treated. The mean follow-up was 40 months. Tumors of the oropharynx were the most frequent (46%) and stage IV predominated (80%). Eighty-nine percent of the patients had received the full radiation treatment as planned. Omission of weekly cisplatin occurred frequently, mainly because of hematological toxicity. Only 64% of the patients completed at least 5 cycles of chemotherapy. Grade 3/4 mucosal toxicity developed in 32% of the patients. The late toxicities were acceptable: 74% of the patients were able to eat solid food during the 1st post-treatment year 4 patients were not able to swallow at all during the 1st post-treatment year, requiring thus permanent feeding tube. Five cases of osteora-dionecrosis of the mandible were reported. Three-year overall survival, locoregional control, time to progression and disease free survival were 34, 60, 52 and 29%, respectively. Conclusion: Definitive radiochemotherapy with weekly cisplatin was toxic, with high rate of morbidity and mortality in this patient population. Five weekly cycles of 40 mg/m(2) cisplatin seem to be the dose limit for most patients. Three-year survival was significantly reduced despite the promising high initial response and locoregional control. Purpose: The objective of this study was to evaluate the feasibility, toxicity and efficacy of definitive radiochemotherapy with weekly cisplatin in head and neck cancer in a single institutional setting. Methods: Previously untreated patients with stage II-IV head and neck cancer were included. Radiotherapy consisted of 70 Gy/7 weeks/35 fractions. All patients received concurrent cisplatin 40 mg/m(2) weekly Results: Between 2/2002 and 8/2009, 148 consecutive patients (WHO <= 2, male to female ratio 6/1, median age 56 years) were treated. The mean follow-up was 40 months. Tumors of the oropharynx were the most frequent (46%) and stage IV predominated (80%). Eighty-nine percent of the patients had received the full radiation treatment as planned. Omission of weekly cisplatin occurred frequently, mainly because of hematological toxicity. Only 64% of the patients completed at least 5 cycles of chemotherapy. Grade 3/4 mucosal toxicity developed in 32% of the patients. The late toxicities were acceptable: 74% of the patients were able to eat solid food during the 1st post-treatment year 4 patients were not able to swallow at all during the 1st post-treatment year, requiring thus permanent feeding tube. Five cases of osteora-dionecrosis of the mandible were reported. Three-year overall survival, locoregional control, time to progression and disease free survival were 34, 60, 52 and 29%, respectively. Conclusion: Definitive radiochemotherapy with weekly cisplatin was toxic, with high rate of morbidity and mortality in this patient population. Five weekly cycles of 40 mg/m(2) cisplatin seem to be the dose limit for most patients. Three-year survival was significantly reduced despite the promising high initial response and locoregional control.
dcterms:title
Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis
skos:prefLabel
Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis
skos:notation
RIV/00064211:_____/12:#0000213!RIV14-MZ0-00064211
n14:predkladatel
n16:ico%3A00064211
n3:aktivita
n7:I
n3:aktivity
I
n3:cisloPeriodika
3
n3:dodaniDat
n8:2014
n3:domaciTvurceVysledku
n9:1976478 n9:1053434 n9:4887328 n9:1772635
n3:druhVysledku
n12:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
129859
n3:idVysledku
RIV/00064211:_____/12:#0000213
n3:jazykVysledku
n10:eng
n3:klicovaSlova
radiochemotherapy; head and neck cancer; concomitant chemoradiotherapy; cisplatin
n3:klicoveSlovo
n4:cisplatin n4:head%20and%20neck%20cancer n4:radiochemotherapy n4:concomitant%20chemoradiotherapy
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[2E07233154E7]
n3:nazevZdroje
Journal of BUON
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
7
n3:rokUplatneniVysledku
n8:2012
n3:svazekPeriodika
17
n3:tvurceVysledku
Dvořák, J. Kubeš, Jiří Pála, Miloslav Holečková, Petra Podlešák, Tomáš Vítek, Pavel Odrážka, Karel
n3:wos
000309793000010
s:issn
1107-0625
s:numberOfPages
7